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The evidence for the benefits of postop-
erative radiotherapy to the whole breast 
(WBI) has been further substantiated 
since the last recommendations on the ba-
sis of updated meta-analyses, systematic 
reviews, and randomized controlled trials. 
Depending on tumor stage, WBI reduc-
es in-breast recurrences as well as region-
al relapses [23, 24, 27]. To date, there are 
no conclusive data from prospective clin-
ical investigations about predictive genet-
ic and/or molecular markers on response 
to radiotherapy
Endocrine therapy can reduce or de-
lay locoregional recurrences, however, 
not distinctive and sustainable enough to 
compensate the deterioration of local con-
trol when WBI is omitted in any age or 
risk group [27, 68, 77].
The EBCTCG meta-analysis 
2011 [27]
In its recent quinquennial meta-analysis 
update, the Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) included 
17 randomized studies comparing post-
operative radiotherapy vs. none and com-
prised 7 new studies in addition to previ-
ously reported trials. A total of 10,801 pa-
tients with pT1–2 tumors were recorded: 
the majority of whom (n=7287) were node 
negative, 1050 were node positive, and in 
2464 patients the nodal status was un-
known.
The effect of radiotherapy on 10-year 
recurrences of any type and their rela-
tion to the 15-year breast cancer death 
rates were studied in correlation to vari-
ous prognostic parameters and treat-
ment characteristics. The absolute risk of 
any first recurrence was adjusted for tri-
al, individual follow-up year, nodal status, 
and age (five groups), and also for tumor 
grade, tumor size, estrogen-receptor (ER) 
status, and whether or not tamoxifen had 
been used in both randomized groups.
Overall, WBI reduced the 10-year re-
currence rate (local or distant) from 35 to 
19.3%, corresponding to an absolute ben-
efit of 15.7% (2p<0.0001) for irradiated 
women (pN0: 15.4%, pN+: 21.2%). The 
 
Statement RT 1 (Leitlinienprogramm 2012) 
[74]
In invasive breast carcinoma, postopera-
tive radiotherapy following breast conserving 
surgery has to be performed (LoE 1a, GR A),
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10-year rate of locoregional recurrence 
as the first event was substantially higher 
for non-irradiated women: 25.1 vs. 7.7%, 
i.e., an absolute difference of 17.4% (pN0: 
15.5%, pN+: 30.8%). Moreover, WBI de-
creased the 15-year breast cancer death 
rate from 25.2 to 21.4%, corresponding 
to an absolute gain of 3.8% (pN0: 3.3%, 
pN+: 8.5%). Finally, radiotherapy reduced 
the 15-year risk of any death from 37.6 to 
34.6%, providing an absolute gain of 3.0% 
(pN0: 2.8%, pN+:10.7%). Mortality with-
out recurrence was slightly but not signifi-
cantly higher in irradiated women [rela-
tive risk (RR) 1.09, 0.97–1.22, 2p=0.14].
In summary, WBI halved the aver-
age annual rate of disease recurrence (RR 
0.52, 0.48–0.56) and reduced the annu-
al breast cancer death rate by about one 
sixth (RR 0.82, 0.75–0.90). On average, in 
all patients, about one breast cancer death 
was avoided per year 15 for every four re-
currences avoided by year 10. Little varia-
tion of the proportional benefit was seen 
in the different prognostic subgroups. In 
contrast, the absolute benefit from radio-
therapy substantially depended on the pa-
tient characteristics in terms of prognos-
tic factors.
 
Comments and conclusion of the  DEGRO 
panel
F		This important large-scale meta-
analy sis impressively confirmed that 
prevention of locoregional recur-
rences by postoperative radiotherapy 
translates into improved survival.
Radiotherapy in the elderly
The indication for WBI for women over 
70 years with low risk tumors is an ongo-
ing issue of international debate with par-
tially antipodal interpretations [77]. The 
updated recommendations of the Euro-
pean Society of Breast Cancer Specialists 
(EUSOMA) [14] and the latest German 
S3 guidelines define no age limitation for 
postoperative RT for healthy elderly pa-
tients. Albeit the absolute benefit of adju-
vant treatment is smaller in advanced age, 
the proportional risk reduction by half is 
constantly observed [3, 17, 22, 24, 27, 41, 
66, 68, 69, 75, 84, 88, 89, 93, 94, 96]. In 
the EBCTCG 2011 analysis, even in node-
negative patients over 70 years the 10-year 
recurrence rate was reduced from 17.7 to 
8.8% [27].
Data from population-based analy-
ses reveal that refraining from RT in el-
derly patients is relatively common, con-
secutively leading to higher breast cancer 
mortality [38, 91].
No subgroup has yet been identified in 
whom patients did not profit from RT af-
ter BCS in terms of improved local tumor 
control. Therefore, omission of RT in pa-
tients of advanced age even with favorable 
prognostic factors (pN0, ER-positive, low 
grade) should only be considered in pres-
ence of comorbidities with a substantial 
reduction of life expectancy. This deci-
sion has to be properly documented [9, 
35, 38, 75, 81, 85].
 
Comments and conclusion of the DEGRO 
panel
	
F		Chronological age alone is not an 
appropriate criterion for decision 
against or in favor of adjuvant treat-
ment.
F		No subgroup of elderly patients has 
yet been identified that did not profit 
from RT in terms of local control.
F		The DEGRO breast cancer expert 
panel explicitly discourages determi-
nation of a certain age for the omis-
sion of postoperative RT in healthy el-
derly women with low risk breast can-
cer.
F		In frail elderly women omission of 
postoperative RT should be individ-





A local dose escalation (boost) to the 
tumor bed reduces local recurrence rates 
without demonstrating a survival advantage. 
A tumor bed boost is generally indicated 
(LoE 1a, GR A).
Statement RT 2e [74]
In postmenopausal patients with very 
low risk tumors (in particular >60 years of 
age, small tumors, good prognostic features), 
the absolute benefit of a tumor bed boost is 
smaller. In this subgroup, its omission may be 
considered (LoE 2a, GR C),
 
Considering the tumor bed as the  area 
at highest risk for subclinical tumor cell 
contamination, a local dose escalation fol-
lowing WBI with 50 Gy has proven to de-
crease in-breast recurrence rates most ef-
fectively. The beneficial impact of an ad-
ditional 16 Gy boost dose to the tumor 
bed by either fractionated external beam 
treatment or brachytherapy was cor-
roborated in a follow-up analysis of the 
EORTC trial data, where local recur-
rence rates were consistently shown to be 
halved in every patients’ age group com-
pared to WBI alone [4, 8, 67]. The high-
est benefit in terms of absolute risk reduc-
tion was demonstrated in younger women 
and patients at higher risk of local relapse. 
The boost technique (electrons, external 
beam photons or brachytherapy) had no 
significant impact on the oncologic out-
come [44]. In this trial, higher local con-
trol rates achieved by boost radiotherapy 
did not translate into better survival.
Annual recurrence rates have de-
creased steadily during the last 10 years, 
due to quality progress in diagnostics, 
surgery, pathologic work up, frequent use 
of modern systemic therapy, and partic-
ularly, rapid innovation in radiotherapy. 
Interim reports of the ongoing prospec-
tive Young Boost Trial (NCT0021212) or 
closed ELIOT trial (WBI group) [62] de-
scribe low recurrence rates of estimated 
0.5% after 4 years (age group <50 years) 
and 0.7% after 5 years, respectively [7, 65], 
pointing at the value of further dose aug-
mentation in the tumor bed.
The following techniques are used for 
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DEGRO practical guidelines: radiotherapy of breast cancer I. Radiotherapy 
following breast conserving therapy for invasive breast cancer
Abstract
Background and purpose. The aim of the 
present paper is to update the practical 
guidelines for postoperative adjuvant radio-
therapy of breast cancer published in 2007 by 
the breast cancer expert panel of the German 
Society for Radiooncology (Deutsche Gesell-
schaft für Radioonkologie, DEGRO). The pres-
ent recommendations are based on a revision 
of the German interdisciplinary S-3 guide-
lines published in July 2012.
Methods. A comprehensive survey of the 
literature concerning radiotherapy follow-
ing breast conserving therapy (BCT) was per-
formed using the search terms “breast can-
cer”, “radiotherapy”, and “breast conserving 
therapy”. Data from lately published meta-
analyses, recent randomized trials, and guide-
lines of international breast cancer socie ties, 
yielding new aspects compared to 2007, pro-
vided the basis for defining recommenda-
tions according to the criteria of evidence-
based medicine. In addition to the more gen-
eral statements of the DKG (Deutsche Krebs-
gesellschaft), this paper addresses indica-
tions, target definition, dosage, and tech-
nique of radiotherapy of the breast after con-
servative surgery for invasive breast cancer.
Results. Among numerous reports on the 
effect of radiotherapy during BCT published 
since the last recommendations, the recent 
EBCTCG report builds the largest meta-analy-
sis so far available. In a 15 year follow-up 
on 10,801 patients, whole breast irradiation 
(WBI) halves the average annual rate of dis-
ease recurrence (RR 0.52, 0.48–0.56) and re-
duces the annual breast cancer death rate by 
about one sixth (RR 0.82, 0.75–0.90), with a 
similar proportional, but different  absolute 
benefit in prognostic subgroups (EBCTCG 
2011).
Furthermore, there is growing evidence 
that risk-adapted dose augmentation strat-
egies to the tumor bed as well as the imple-
mentation of high precision RT techniques 
(e.g., intraoperative radiotherapy) contrib-
ute substantially to a further reduction of lo-
cal relapse rates. A main focus of ongoing re-
search lies in partial breast irradiation strate-
gies as well as WBI hypofractionation sched-
ules. The potential of both in replacing nor-
mofractionated WBI has not yet been  finally 
clarified.
Conclusion. After breast conserving surgery, 
no subgroup even in low risk patients has yet 
been identified for whom radiotherapy can 
be safely omitted without compromising lo-
cal control and, hence, cancer-specific sur-
vival. In most patients, this translates into an 
overall survival benefit.
Keywords
Breast conserving therapy · Whole breast 
irradiation · Partial breast radiotherapy · Boost 
radiotherapy · Fractionation
DEGRO-Leitlinien für die Radiotherapie des Mammakarzinoms I. Radiotherapie 
nach brusterhaltender Operation invasiver Mammakarzinome
Zusammenfassung
Zielsetzung. Aktualisierung der DEGRO-
Leitlinien von 2007 zur Radiotherapie (RT) 
invasiver Mammakarzinome nach bruster-
haltender Operation. Die hier präsentier-
ten Empfehlungen basieren auf der inter-
disziplinären S3-Leitlinie der Deutschen 
Krebs gesellschaft, deren aktuelle Version 
2012 publiziert wurde.
Methodik. Die DEGRO-Expertengruppe 
Mammakarzinom führte eine Literaturre-
cherche aktueller klinisch kontrollierter Stu-
dien, systematischer Reviews und Metaana-
lysen sowie Leitlinien internationaler Gesell-
schaften im Hinblick auf neue Aspekte ge-
genüber 2007 durch, wobei sie sich an den 
Kriterien evidenzbasierter Medizin orien-
tierte. Suchbegriffe waren „breast cancer“, „ra-
diotherapy“ und „breast conserving therapy“. 
Ergänzend zu den allgemeineren Statements 
der S3-Leitlinie zielt diese Arbeit auf Indika-
tionsstellung, Zielvolumendefinition, Dosie-
rung und Techniken einer Bestrahlung nach 
brusterhaltender Operation invasiver Mam-
makarzinome.
Ergebnisse. Von den zahlreichen Publika-
tionen, die im Intervall seit den letzten DE-
GRO-Empfehlungen erschienen sind, stellt 
der rezente EBCTCG-Bericht aus dem Jahr 
2011 die bislang zahlenmäßig größte Meta-
analyse dar. In einer 15-Jahres-Nachbeobach-
tung an 10.801 Patienten konnte gezeigt 
werden, dass eine Ganzbrustbestrahlung 
die jährliche Rezidivrate halbiert (RR 0,52; 
0,48–0,56) und die jährliche Rate der Brust-
krebssterblichkeit um ein Sechstel reduziert 
(RR 0,82; 0,75–0,90), mit ähnlicher proportio-
naler, aber unterschiedlicher absoluter Aus-
prägung in prognostischen Untergruppen 
(EBCTCG 2011).
Darüber hinaus besteht zunehmende Evi-
denz, dass risikoadaptierte Strategien einer 
Dosiserhöhung im Tumorbett sowie die An-
wendung hochpräziser RT-Techniken (z. B. 
IORT) entscheidend zu einer weiteren Reduk-
tion der Lokalrezidivraten beitragen. Ein 
Schwerpunkt der aktuellen Forschung liegt 
in der Evaluierung von Techniken der Par-
tialbrustbestrahlung sowie im Einsatz hy-
pofraktionierter Dosierungsschemata in der 
Ganzbrustbestrahlung. Das Potenzial beider 
Strate gien, eine normofraktionierte Ganz-
brustbestrahlung zu ersetzen, ist derzeit nicht 
abschließend geklärt.
Schlussfolgerungen. Nach brusterhalten-
der Operation invasiver Mammakarzinome 
konnte selbst bei Niedrigrisiko-Patientin-
nen bislang keine Subgruppe identifiziert 
werden, bei der auf eine nachfolgende Ra-
diotherapie verzichtetet werden kann, oh-
ne die lokale Tumorkontrolle und in weite-
rer Folge das krebsspezifische Überleben zu 
beeinträchtigen. Überdies resultiert bei den 
meisten Patientinnen durch die Bestrahlung 
ein Überlebensvorteil.
Schlüsselwörter
Brusterhaltende Therapie · 
Ganzbrustbestrahlung · 
Partialbrustbestrahlung · Boostbestrahlung · 
Fraktionierung
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and electrons, interstitial and endolumi-
nal brachytherapy, and intraoperative ra-
diotherapy with electrons (IOERT) or in 
selected cases with low-energy photons 
(kV). Intraoperative, interstitial, and en-
doluminal techniques differ enormously 
in terms of dose distribution. Thus, out-
come analyses of local control rates have 
to be performed according to the used 
method. IOERT has been demonstrated 
to be the method delivering the utmost 
uniform dose distribution within a giv-
en target volume [55]. Boost treatments 
by protons are considered to be experi-
mental.
In the EORTC boost trial a dose of 
16 Gy was used either in 8 fractions of 
2 Gy EBRT or as low dose rate brachy-
therapy using 192-iridium implants with 
a dose rate of 0.5 Gy/h. In the French ran-
domized trial, Romestaing et al. [71] ap-
plied 10 Gy in 2 Gy single doses; updated 
results have not been published. A sub-
group analysis of the EORTC boost trial 
[67] assessed the outcome of 251 patients 
with R1 resection who were random-
ized to receive either a 10 Gy or a 26 Gy 
boost. There was no statistically signifi-
cant difference in local control or surviv-
al between the lower and the higher boost 
dose group. Fibrosis occurred significant-
ly more often after 26 Gy. Extrapo lating 
these results on patients with complete re-
section, it seems justifiable to use a 10 Gy 
boost, even though data are less valid than 
for 16 Gy [74]. In a European survey about 
current practice in breast RT, one third of 
the institutions used a 10 Gy boost dose 
[90].
In recent years, an additional focus of 
boost therapy has been placed on accel-
erated dose integration during the course 
of WBI, which is possible using different 
approaches: during simultaneously inte-
grated boosts (SIB, concomitant boost), 
the boost dose is administered by dai-
ly zonal dose augmentations [32, 78]. In-
traoperative treatments precede WBI and 
are performed either with kV-photons or 
electrons. For IOERT, long-term follow-
up data are available, indicating excellent 
high local tumor control rates in every 
risk group [29].
 
DEGRO comments and conclusions
F		A boost in addition to WBI reduc-
es local recurrence in all age groups 
and should, therefore, be offered to 
patients who appear biologically and 
mentally fit enough to experience the 
benefit of improved local control.
F		For the remaining patients especial-
ly when they are >60 years with small, 
node-negative, hormone receptor-
positive tumors, omission of a boost 
may be considered.
F		Regarding SIB techniques within nor-
mofractionated WBI, single tumor 
bed doses of 2.1 Gy for low-risk tu-
mors (equal to a sequential boost with 
5×2 Gy to 10 Gy) up to 2.25 Gy for 
constellations with higher risk of lo-
cal recurrence (equal to a boost with 
8×2 Gy to 16 Gy) seem to be within 
the acceptable range.
Hypofractionated radiotherapy 
in breast cancer treatment 
For breast cancer cells, a higher sensitivity 
towards single doses >2 Gy has been pos-
tulated in radiobiological models, due to a 
lower alpha/beta (α/β) ratio with estimat-
ed values around 4 Gy in contrast to val-
ues of ten assumed for squamous cell car-
cinoma (SCC). This principle was exploit-
ed in whole breast radiotherapy (WBI) as 
well as accelerated partial breast irradia-
tion (APBI) including intraoperative pro-
cedures (IORT) and SIB techniques [78].
Four randomized clinical trials (Start 
A, Start B, Owen, Whelan) investigat-
ed hypofractionated WBI schedules (39–
42.9 Gy in single fractions of 2.6–3.3 Gy) 
for iso-effectiveness compared to normo-
fractionation (50 Gy in single fractions of 
2 Gy). In summary, 7095 patients were 
treated within these trials, 89.8% with tu-
mors <3 cm, 79% node negative, 87% had 
small or medium-sized breasts. Only a 
minority was treated with chemotherapy, 
practically no experience exists with the 
use of taxanes in combination with HF-
WBI.
In hypofractionated groups of the 
START trials, local recurrence rates at 5 
and 10 years were reported in the range of 
2.2–3.6% and 9.1–14.8%, respectively. In 
comparison to standard treatment arms, 
showing 5 and 10 year IBRs of 3–3.6% and 
12.1%, respectively, corresponding results 
of the experimental arms showed a trend 
to be superior without statistical signifi-
cance, providing equal long-term cosmet-
ic outcome [11, 12, 63]. The 10-year follow-
up data were presented at the SABCS 2012, 
corroborating the previous reports [39].
The Canadian trial also confirms these 
findings in long-term analyses [95], with 
a possible exception of high-graded tu-
mors, where hypofractionated schedules 
resulted in lower tumor control rates. This 
was in contrast to other data [40]. To date, 
ultrashort WBI courses are tested in the 
FAST trial (faster radiotherapy for breast 
cancer), where a 5-fraction schedule of 
whole breast radiotherapy is compared 
against the UK standard 15-fraction reg-
imen in terms of local cancer control and 
late adverse effects [2].
Cosmesis after 5 years was evaluated 
in about half of the patients. Long-term 
follow-up >5 years was published in one 
study [40]. In a Cochrane meta-analysis 
[43], the authors stated that the findings 
of their review provided reassurance that 
offering HF to carefully selected patients 
is unlikely to be detrimental in terms of 
local control, breast appearance, survival, 
or late radiation breast toxicity for women 
with small to medium breasts, aged great-
er than 50 years, with small, node-nega-
tive tumors. The authors emphasize that 
longer follow-up is needed to finally assess 
the effects of HF. In accordance with these 
concerns, the ASTRO consensus and the 
German guidelines additionally recom-
mend to refrain from HF when a homog-
enous dose is not achievable [74, 80].
Moreover, the impact of HF on late 
cardiac toxicity is not yet evaluated be-
yond 10 years [57, 95]; as the latency for 
clinical manifestation of cardiovascular 
effects is 15 years or longer, HF might turn 
out to be critical in cases of relevant dose 
 
Statement RT 2c [74]
In elderly patients with tumors <5 cm and 
without locoregional lymph node disease, 
who do not receive chemotherapy, as alterna-
tive to normofractionated WBI, hypofraction-
ated schedules (e.g. 5×2.666 Gy/week up to 
40 Gy) may be considered (LoE 1a, GR B),
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exposure to the heart, especially in wom-
en with a longer life expectancy.
Conventional fractionation with a total 
dose of 50–50.4 Gy in single doses of 1.8–
2 Gy is still regarded as standard in all cur-
rent guidelines [9, 56, 74]. Divergence ex-
ists concerning the appraisal of hypofrac-
tionation as a routinely applicable alterna-
tive [9, 74] or as an option restricted to se-
lected patients [74, 80].
Unresolved issues address the effec-
tiveness in selective histologic subtypes 
(e.g., G3), a potentially worse cosmet-
ic outcome in (very) large breasts and 
late normal tissue tolerance, especially in 
combination with modern chemothera-
py regimen. Radiobiological models and 
first clinical results seem to predict infe-
rior outcome for the ongoing ultrashort 
WBI trials [2].
 
Comments and conclusion of the DEGRO 
panel
	
F		Normofractionated WBI plus sequen-
tial boost remains standard.
F		Hypofractionated WBI with sin-
gle doses up to 2.7 Gy in 15–16 frac-
tions to total doses of 40–42 Gy is an 
option for older women with pT1–2 
pN0 tumors who need no chemother-
apy. The additional use of a sequential 
boost is possible.
F		Hypofractionated WBI plus boost ei-
ther by SIB or by hypofractionated se-
quential application is discouraged 
outside clinical trials.
Targeting, treatment planning, 
and technique for the WBI
Individual CT-based 3D planning is man-
datory. Several anatomically-based in-
struction guidelines have been published 
for definition of the planning target vol-
ume (PTV) [58, 73] which includes the 
mammary gland and the adjacent chest 
wall. Organs at risk (OAR) like lung and 
heart (in left-sided tumors possibly with 
delineation of the left anterior coronary 
artery) [30, 58] are contoured and doses 
documented in dose–volume histograms 
(DVH). For planning and treatment, pa-
tients usually are placed in supine posi-
tion with elevated arms in immobiliza-
tion cradles.
For WBI, homogeneity requirements 
in dose distribution as described by 
the ICRU reports 50 and 62 are usually 
achieved by conformally shaped tangen-
tial wedged field techniques, mostly with 
photons at energies of 4–8 MV. For larg-
er breasts, higher energies and/or inten-
sity modulation (IMRT) within the tan-
gential beams may be appropriate to ful-
fill the minimum homogeneity criteria [6, 
42]. Multi-angle IMRT may be beneficial 
for patients with difficult anatomical con-
ditions (i.e., funnel chest) where tangen-
tial field arrangements would lead to ex-
cessive exposure of OARs. However, the 
routine use of multi-angle IMRT tech-
niques is problematic due to the increased 
volume exposed to low doses [50]. There-
fore, a potentially increased risk of sec-
ondary tumor induction must be weighed 
against sparing of OAR [26, 37]. In select-
ed cases, WBI in prone position might al-
so serve as alternative [45]. The use of ac-
tive breathing control, such as computer-
assisted breath hold in deep inspiration 
[83, 99] provides another possibility of 
sparing radiation burden to the lungs and 
for left-sided tumors also to cardiac struc-
tures as it increases the distance between 
target volume and heart [49].
For quality control, correct treatment 
delivery has to be documented with re-
peated imaging, mostly by EPIDs or kV-
based image guidance, alternatively by op-
tical surface scanning techniques [34].
Radiotherapy following 
neoadjuvant chemotherapy 
and breast conserving surgery
The abovementioned statement is part 
of the S3 recommendations concerning 
postmastectomy radiotherapy (PMRT). 
Of note, the S3 guidelines do not explic-
itly provide information on adjuvant ra-
diotherapy after breast conserving surgery 
subsequent to primary systemic treatment 
(PST). Usually, patients referred to PST 
are also considered to be at higher risk for 
a locoregional relapse, thus, emphasiz-
ing the need for an amplified locoregion-
al treatment. Hence, and in the absence of 
randomized prospective trials, indications 
for radiotherapy following BCS are not al-
tered by the time sequencing of the sys-
temic medications.
A major goal of neoadjuvant chemo-
therapy in advanced breast cancer cas-
es is to facilitate breast conserving treat-
ment without compromising local control 
(LC) and survival rates. Prospective and 
retrospective data of the 1990s up to 2010 
verified the feasibility of a multimodal-
ity treatment including WBI after breast 
conserving surgery as an indispensable 
component. However, its optimal use is a 
matter of controversy due to presumably 
higher regional recurrence (RR) and in-
breast relapse (IBR) rates which were re-
ported in a dimension of 10.5% (range 1.8–
22.5) and 8% (range 1.8–17), respectively, 
after median follow-up periods of 5 years 
(range 29–124 months) [13, 15, 19, 20, 21, 
31, 51, 52, 53]. Omission of surgery result-
ed in higher LR rates [51].
During the last decade, data on low-
est locoregional recurrence (LRR) rates 
following postoperative radiotherapy af-
ter neoadjuvant CT were provided by 
two retrospective studies [13, 20, 21]. WBI 
was performed in conventional fraction-
ation (1.8–2 Gy) up to a total dose of 45–
50 Gy, followed by a fractionated tumor 
bed boost with external electrons with 
doses between 10 and 20 Gy. In these 
trials, pathological complete response 
(pCR) rates around 23.5% were achieved 
after PST. At median follow-up times of 
60 months, compiled rates (mean val-
ues) of LRR, IBR, and distant metastasis 
amounted to 8, 4.5, and 19%, respective-
ly. In contrast, results of prospective tri-
als are less favorable, reporting mean IBR 
rates of about 9.6% after a median follow-
up of 68.4 months (range 29–124 months) 
[15, 18, 19, 31, 52, 72]. However, these re-
ports lack precise information on radio-
therapy details (e.g., boost techniques and 
their dose prescription). Improvement of 
local control by radiation dose escalation 
(e.g., by IOERT) is a promising strategy, 




After primary (neoadjuvant) systemic 
therapy, the indication for adjuvant radio-
therapy follows pretherapeutic TN-categories 
irrespective of response to the primary sys-
temic treatment (LoE 2A, GR A).
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Conclusion of the DEGRO panel
F		Normofractionated WBI following 
PST (primary systemic therapy) is 
mandatory during BCT irrespective 
of achieved response.
F		A focus of interest is the investiga-
tion of dose augmentation to the tu-
mor bed (e.g., by altered fractionation 
and/or total dose escalation) for pos-
sible compensation of higher local re-
lapse rates.
Partial breast irradiation
Accelerated partial breast irradiation 
(APBI) refers to RT of a smaller (partial) 
breast volume over a shorter time inter-
val, covering the tumor bed with a limit-
ed margin of normal tissue. For patients at 
a lower risk for local recurrence, APBI has 
been strongly propagated in recent years 
as it spares treatment time, costs, and al-
legedly provides less toxicity [54]. AP-
BI can be delivered intra-operatively in 
a single fraction or postoperatively over 
1–3 weeks by brachytherapy or external 
beam radiotherapy. In analogy to boost 
settings, these methods differ in terms of 
physical dose distribution and radiobio-
logic effects, which has to be considered 
in outcome analyses [55, 59].
Cinical evidence
So far, only four phase III randomized 
trials and one meta-analysis evaluating 
 APBI have been published. Three of these 
studies have important limitations: The 
Yorkshire Breast Cancer Group trial [25] 
failed to complete accrual and used a va-
riety of techniques. In the Christie Hospi-
tal trial [70], 708 patients were random-
ized between APBI and WBI, but lacked 
appropriate target volume definition cri-
teria; moreover, many patients outside the 
low-risk group were entered. The Hungar-
ian trial comparing WBI with APBI using 
HDR implants or electrons (normal frac-
tionation) was prematurely stopped af-
ter recruitment of 258 women with mar-
gin-negative, early-stage breast cancers, 
thus, lacking sufficient sample size [64]. 
A meta-analysis of these phase III tri-
als was published in 2010 [87] Compared 
to WBI, APBI was associated with an in-
creased risk for both local [pooled odds 
ratio (OR) 2.15; p=0.001] and regional re-
currence (pooled OR 3.43; p<0.001), how-
ever, not (yet) translating into a survival 
difference (OR 0.91; p=0.55) [54]. Ortho-
voltage IORT as APBI strategy was inves-
tigated in the TARGIT trial as the fourth 
published randomized investigation and 
is discussed below.
Intraoperative radiotherapy
To date, two major “full-dose” IORT 
studies are promoted: the TARGIT ap-
proach using ortovoltage x-rays and the 
 ELIOT trial, respectively, testing single-
shot electron treatment. In 2010, a first 
interim analysis was published from the 
 TARGIT trial at a median follow-up time 
of 24.6 months [86].The Kaplan–Meier 
estimate of local recurrence at 4 years was 
1.2% in the APBI arm and 0.95% in the 
WBI group. The latest update was present-
ed at the 2012 SABCS, with a publication 
awaited. In this analysis of 3,442 patients 
and a median follow-up of 29 months, the 
local failure rate in the TARGIT group 
was 2% higher in comparison to WBI 
(p=0.042, HR=2.05). The frequency of 
any complications and major toxicity was 
similar with both treatment modalities 
(3.3% TARGIT vs. 3.9% WBI).
The ELIOT trial [61] has reached its ac-
crual goal, 651 ELIOT patients were ran-
domly compared to a cohort treated with 
standard WBI, with a publication pend-
ing. First results have been presented, 
alerting a higher IBTR rate in the IORT 
arm [62].Outside this trial setting, an-
other 1822 patients were treated using the 
ELIOT concept [92]. After a median fol-
low-up of 36 months, altogether 3.63% 
in-breast recurrences were observed. Pre-
dictive factors for LR were age <50 years, 
tumor size, grading, involved nodes and 
negative hormone receptors. When ana-
lyzed according to current ASTRO Con-
sensus Statement Guidelines for the ap-
plication of accelerated partial breast ir-
radiation, the 5-year rate of ipsilateral 
breast recurrence for suitable, cautionary, 
and unsuitable groups were 1.5, 4.4, and 
8.8%, respectively (p=0.0003) [48]. Apply-
ing GEC-ESTRO risk criteria, the 5-year 
rate of in-breast tumor reappearances for 
“good candidates” amounted to 1.9%, for 
“possible candidates” and “contraindica-
tion” 7.4 and 7.7%, respectively (p0.001) 
[47].
In light of the existing literature, it 
seems premature to interpret the results 
following sole IORT—by any means—as 
isoeffective compared to standard treat-
ment. True local recurrences are pre-
sumed to occur between 40 and 65 
months after primary treatment [16, 36], 
out-quadrant relapses even later than that 
[33] when WBI was performed. Only ade-
quate long-term experience will reveal the 
potential of a sole IORT approach to re-































Radiotherapy restricted to parts of the 
affected breast (partial breast irradiation, PBI) 
as sole radiation treatment including sole 
intraoperative radiotherapy (IORT) represents 
no treatment standard (LoE 3b).
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